Short-Course Combivir after Single-Dose Nevirapine Reduces but Does Not Eliminate the Emergence of Nevirapine Resistance in Women

Abstract

Short-course CBV significantly reduced but did not eliminate the emergence of NVP resistance after sdNVP. NVP-resistant variants were detected in about one-third of women despite CBV treatment, but the duration of persistence and clinical impact of these variants in response to antiretroviral therapy is uncertain.